2,014 results on '"Shyr, Yu"'
Search Results
102. Supplemental Figure 5 from A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
103. Supplemental Figure 1 from A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
104. Supplemental Figure 4 from A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
105. Supplementary Methods, Figures 1-2, Tables 1-3 from Contribution of Beta-HPV Infection and UV Damage to Rapid-Onset Cutaneous Squamous Cell Carcinoma during BRAF-Inhibition Therapy
106. Tables S7-S8 from The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)
107. Data from A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance
108. Supplementary Methods, Tables 1-4, Figures 1-6 from RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors
109. Supplementary Figures from RNA Sequencing Identifies Transcriptionally Viable Gene Fusions in Esophageal Adenocarcinomas
110. Supplementary Data from A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance
111. Supplemental Figure 2 from A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
112. Supplemental Text_PTEN_MET_IHC methods from The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)
113. Supplemental Figure 3 from A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
114. Supplementary legend from A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
115. Supplemental Table 1 from A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67
116. Data from Lung Cancer Diagnosis from Proteomic Analysis of Preinvasive Lesions
117. Supplementary Figure 1 from A Kinome-Wide Screen Identifies the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer
118. Data from A Kinome-Wide Screen Identifies the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer
119. Supplementary Tables 1-4 from Lung Cancer Diagnosis from Proteomic Analysis of Preinvasive Lesions
120. Data from ALCAM/CD166 Is a TGF-β–Responsive Marker and Functional Regulator of Prostate Cancer Metastasis to Bone
121. Supplementary Figure 1 from Lung Cancer Diagnosis from Proteomic Analysis of Preinvasive Lesions
122. Data from Regulation of ERBB2 Receptor by t-DARPP Mediates Trastuzumab Resistance in Human Esophageal Adenocarcinoma
123. Supplementary Tables 1-2 from Enhanced Hepatocyte Growth Factor Signaling by Type II Transforming Growth Factor-β Receptor Knockout Fibroblasts Promotes Mammary Tumorigenesis
124. Supplementary Methods, Figure Legends 1-3 from Lung Cancer Diagnosis from Proteomic Analysis of Preinvasive Lesions
125. Data from Angiocrine Factors Modulate Tumor Proliferation and Motility through EphA2 Repression of Slit2 Tumor Suppressor Function in Endothelium
126. Data from Elevated ALCAM Shedding in Colorectal Cancer Correlates with Poor Patient Outcome
127. Supplementary Figure 3 from Lung Cancer Diagnosis from Proteomic Analysis of Preinvasive Lesions
128. Supplementary Methods from Elevated ALCAM Shedding in Colorectal Cancer Correlates with Poor Patient Outcome
129. Supplementary Figure 5 from Elevated ALCAM Shedding in Colorectal Cancer Correlates with Poor Patient Outcome
130. Supplementary Figures 1-4 from Angiocrine Factors Modulate Tumor Proliferation and Motility through EphA2 Repression of Slit2 Tumor Suppressor Function in Endothelium
131. Supplementary Methods from Enhanced Hepatocyte Growth Factor Signaling by Type II Transforming Growth Factor-β Receptor Knockout Fibroblasts Promotes Mammary Tumorigenesis
132. Supplementary Figures 1 through 9 from ALCAM/CD166 Is a TGF-β–Responsive Marker and Functional Regulator of Prostate Cancer Metastasis to Bone
133. Supplementary Figure 6 from Elevated ALCAM Shedding in Colorectal Cancer Correlates with Poor Patient Outcome
134. Supplementary Figure 4 from A Kinome-Wide Screen Identifies the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer
135. Supplementary Figure 3 from A Kinome-Wide Screen Identifies the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer
136. Supplementary Figure 1 from Elevated ALCAM Shedding in Colorectal Cancer Correlates with Poor Patient Outcome
137. Supplementary Figure 9 from A Kinome-Wide Screen Identifies the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer
138. Supplementary Figure 6 from A Kinome-Wide Screen Identifies the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer
139. Supplementary Figure 5 from A Kinome-Wide Screen Identifies the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer
140. Supplementary Methods, Figures 1-2 from Regulation of ERBB2 Receptor by t-DARPP Mediates Trastuzumab Resistance in Human Esophageal Adenocarcinoma
141. Supplementary Figure 2 from Elevated ALCAM Shedding in Colorectal Cancer Correlates with Poor Patient Outcome
142. Supplementary Figure 2 from Lung Cancer Diagnosis from Proteomic Analysis of Preinvasive Lesions
143. Supplementary Methods from ALCAM/CD166 Is a TGF-β–Responsive Marker and Functional Regulator of Prostate Cancer Metastasis to Bone
144. Supplementary Figure 7 from A Kinome-Wide Screen Identifies the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer
145. Supplementary Methods, Figure Legends 1-13, Table 1 from A Kinome-Wide Screen Identifies the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer
146. Supplementary Figure 4 from Elevated ALCAM Shedding in Colorectal Cancer Correlates with Poor Patient Outcome
147. Supplementary Tables from Elevated ALCAM Shedding in Colorectal Cancer Correlates with Poor Patient Outcome
148. Supplementary Figure Legends from Elevated ALCAM Shedding in Colorectal Cancer Correlates with Poor Patient Outcome
149. Supplementary Figure Legend from ALCAM/CD166 Is a TGF-β–Responsive Marker and Functional Regulator of Prostate Cancer Metastasis to Bone
150. Supplementary Figure 3 from Elevated ALCAM Shedding in Colorectal Cancer Correlates with Poor Patient Outcome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.